MT-401 for Leukemia
This study is evaluating whether a type of white blood cell called a T-cell may help treat acute myeloid leukemia.
See full descriptionAbout the trial for Leukemia
Treatment Groups
This trial involves 2 different treatments. MT-401 is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
Eligibility
This trial is for patients born any sex aged 18 and older. You must have received 1 prior treatment for Leukemia or one of the other 4 conditions listed above. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether MT-401 will improve 3 primary outcomes in patients with Leukemia. Measurement will happen over the course of Baseline through Cycle 1 (28 Days).
Patient Q & A Section
Can leukemia be cured?
It is not medically possible to cure CLL or AML. Many variables are involved, but the results depend on the leukemia type. When cure is sought, it is usually within the scope of the clinical and scientific community to advise the patient that the illness appears incurable, even though a significant minority of patients respond to treatment options.
What are the signs of leukemia?
Some signs and symptoms of leukemia include malaise, a high white blood count, loss of appetite, and fatigue. Fever may be the most specific sign of leukemia. Other symptoms may signify other types of cancers. Lymphopenia and anemia are common and have led to anemia. Abnormal liver function can show signs of liver cancer. Many other diseases can have similar signs and symptoms and should be evaluated. These include hepatitis, gastrointestinal and skin diseases, and kidney disease.
What are common treatments for leukemia?
Most patients with leukemia receive intensive chemotherapy to achieve prolonged remission. Patients who experience a relapse or have a poor prognosis receive chemotherapy again or receive an autologous stem cell transplant. Radiation therapy plays a less important role in leukemia treatment and is only used in certain patients.
What causes leukemia?
Leukemia is caused by mutations in chromosomal DNA of the blood-forming stem and progenitor cells, rather than from oncoviruses or other exogenous agents. These cells may become transformed, as they divide, leading to the development of leukemias. This presents a problem in the diagnosis of leukemia, because the malignant cells that dominate the leukemia may not be infected by an agent; for example, acute leukemia may develop when a person's lymphocytes are mutated by a toxin, or chronic leukemia may develop when stem cells are mutated by a virus.
How many people get leukemia a year in the United States?
Each year, about 26.6 million people in the USA will be diagnosed with leukemia. This makes it the second most common lethal cancer in the US after lung cancer...
What is leukemia?
Leukemia is a cancer of the blood platelets, bone marrow, liver or lymphatic system. It can occur in adults (18-40 years) or children and adolescents, but most cases occur in adults.
What are the chances of developing leukemia?
The chances of getting leukemia increase as a person gets older. This effect is particularly prominent among males older than 80 years of age. The reason for this increase is not known. However, it is likely that it is linked to some environmental or lifestyle factor that becomes exposed to an increased frequency in older persons.
What does mt-401 usually treat?
It does not kill the tumors but may shrink tumor tissue and prevent future growth by depriving it of certain essential nutrients. It boosts cell growth and tumor growth in part by activating the IGF1 signaling pathway at certain tumor sites, but also at distant sites. It also activates this pathway at a variety of tumor sites. In human preclinical models, it was well tolerated but had only minor activity. None are currently in phase III clinical trials but as of February 2019, there are indications that the drug has been discontinued.\n\nIn 2013, Dr.
What is the survival rate for leukemia?
There is significant variation in the survival rates of individuals with all CLL and CML, especially in those with early disease. Overall survival in CLL is better than the general population, and survival rates are similar for males and females. Survival in CML is shorter than general life expectancy. Overall survival for both CLL and CML are greater than 10 years, the current limit for remission of CLL or CML.
How quickly does leukemia spread?
Patients with primary CLL or [hairy cell leukemia](https://www.withpower.com/clinical-trials/hairy-cell-leukemia) (a rare type of leukemia) who went into complete remission from their diagnosis to the time of relapse showed the fastest rate of disease progression (on average, 11.8 months) and had the most progressive leukemia, including the leukemia cells in the bone marrow and blood, compared with those of the remaining patients. A significant factor influencing the progression of leukemia is the severity of the disease when detected. Patients with newly diagnosed chronic stage 2 or even acute stage 1 disease had the shortest average progression times (3.1 and 9.6 months, respectively). The progression times after the initial diagnosis of chronic B-cell illnesses were the slowest (5.
What is the average age someone gets leukemia?
From the data that has been collected in various countries, the average age of diagnosis seems to be 52 years. Findings from a recent study the gender ratio of patients is slightly less than half, which is approximately the ratio that is seen in the population
Who should consider clinical trials for leukemia?
Patients are a good cohort of physicians to recruit for clinical trials. It is particularly important for a trial to include a population that is not being treated by other physicians in order to avoid skewing data towards results based on convenience rather than research. Once a trial has recruited enough patients, it may be reasonable to ask patients to donate blood before taking part in the study. When this is not possible or advisable, it may be acceptable to ask that patients return annually for blood donation as part of the study.